FY2024 · ended Dec 31, 2024 · Revenue $7.81M, +7.0% YoY · Filed Jun 16, 2026
Pulmatrix, Inc. (PULM) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$7.81M
+7.0% vs prior year
Net income
$-5.16M
+46.0% vs prior year
Operating cash flow (TTM)
$-3.91M
+51.2% vs year-ago TTM
Free cash flow
$-11.11M
+33.3% vs prior year
EPS
$-1.41
+46.2% vs prior year
Dividend per share
None
Shares outstanding
3.65M
+0.0% vs prior year
Net cash
$10.42M
FY 2023
Operating margin
-125.1%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PULM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Framingham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1574235
- Former names
- Ruthigen, Inc. (until Jun 16, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $7.8M | $7.3M | $6.1M | $5.2M |
| Operating income | -$5.2M | -$9.8M | -$14.7M | -$18.9M | -$20.2M |
| Net income | -$5.2M | -$9.6M | -$14.1M | -$18.8M | -$20.2M |
| Diluted EPS | -$1.41 | -$2.62 | -$3.87 | — | — |
| Operating cash flow | -$5.4M | -$10.7M | -$16.0M | -$19.4M | -$19.7M |
| Free cash flow | — | -$11.1M | -$16.7M | -$19.4M | -$19.9M |
| Total assets | $4.1M | $9.9M | $34.0M | $41.0M | $58.8M |
| Total liabilities | $329,000 | $996,000 | $16.0M | $9.8M | $11.4M |
| Stockholders' equity | $3.8M | $8.9M | $18.0M | $31.1M | $47.4M |
| Cash and investments | $4.1M | $9.5M | $19.2M | $35.6M | $53.8M |
| Total debt | — | — | $8.8M | $857,000 | $2.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 27, 2026 | Oct 26, 2026 |
| ARS | Annual report to shareholders | Oct 5, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-K/A | Amended annual report | Jun 16, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
All 652 Pulmatrix, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.